• Human PBMC-engrafted humanized mice are attractive models for in vivo analysis of human immune responses. We previously reported the successful engraftment of human PBMCs in B-NDG mice. However, due to the severe xenograft versus host disease (xeno-GvHD) in these mice, the experimental window is limited. The pathogenesis of GvHD is directly related to human T cell implantation, and the mismatch between human and mouse MHCs is the main cause of GvHD after human PBMCs engraftment. It has been shown that knocking out MHC I and/or II molecules in mice can reduce GvHD and extend the experimental window after engraftment of human PBMCs.
• MHC class I molecules are composed of two subunits, α and β chains, and the α chain in NOD background strain of mice is encoded by H2-K1, H2-D1 gene. Knocking out H2-K1 and H2-D1 gene in mice makes it unable to form a complete MHC Class I molecule. MHC class II molecules are also composed of two subunits, α and β chains, and the β chain is encoded by H2-Ab1 gene. Knocking out H2-Ab1 gene in mice makes it unable to form a complete MHC Class II molecule. These incomplete MHC Class I and MHC Class II molecules will not be able to effectively express on the cell surface and perform antigen-presenting functions, thereby potentially reducing the occurrence of GvHD.
• Human IL15 is a key homeostatic cytokine for peripheral NK cells, promoting their survival, expansion, and functional maturation, and it also supports CD8 T-cell maintenance and effector function. In PBMC-humanized mice, expression of hIL-15 enhances overall human immune reconstitution, with a particularly pronounced improvement in NK-cell engraftment and persistence. Depending on the study design, IL15–driven immune activation may also modulate T-cell expansion and function. 
• Application: B-NDG hIL15, MHC I/II DKO ad mice can be used to enhance PBMC-driven human immune reconstitution—especially T cells and NK cells—while reducing GvHD for immuno-oncology and immune cell therapy studies.

B-NDG hIL15, MHC I/II DKO ad mice has a long life span and reduced severity of GvHD when engrafted with human PBMCs. B-NDG hIL15, MHC I/II DKO ad mice were engrafted intravenously with human PBMCs (1×10⁷) on day 0 (n=5). Survival rates of the mice were analyzed with Kaplan Meier survival curves. Body weight was measured twice a week. Clinical signs of GvHD were scored once a week. Euthanasia was implemented when the body weight decreased more than 20%. Meanwhile, the GvHD score of the mouse was recorded as 10. Values were expressed as mean ± SEM.

Human PBMCs were successfully reconstituted in B-NDG hIL15, MHC I/II DKO ad mice. B-NDG hIL15, MHC I/II DKO ad mice were engrafted intravenously with human PBMCs (1×10⁷) from two donors on day 0 (n=5). Peripheral blood was taken to analyze the reconstitution level of human immune cells. A. Frequency of reconstituted human immune cells; B. Absolute cell number of reconstituted human immune cells. The results showed that two weeks after the reconstitution of human PBMCs in B-NDG hIL15, MHC I/II DKO ad mice, the frequency and absolute cell number of CD45+ cells in peripheral blood began to increase. The frequency of reconstituted human T cells exceeded 90% from three weeks and continued to rise, eventually reaching nearly 100%. Reconstituted human T cells include CD4+T cells, CD8+T cells and Tregs. A small amount of NK cells and NKT-like cells can also be detected. Values were expressed as mean ± SEM.